Global Artificial Tears Industry

29 Feb, 2016, 18:55 ET from Reportlinker

NEW YORK, Feb. 29, 2016 /PRNewswire/ -- This report analyzes the worldwide markets for Artificial Tears in US$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 68 companies including many key and niche players such as -

Abbott Medical Optics Inc.
Allergan, Inc.
Akorn, Inc.
Bausch & Lomb Incorporated
Johnson & Johnson



Read the full report: http://www.reportlinker.com/p0960376-summary/view-report.html



I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1 Disclaimers.............. I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW.............. II-1 Dry Eyes - An Emerging Lucrative Segment of Ophthalmology Market II-1 Table 1: Global Ophthalmology Market (2015): Percentage Share Breakdown by Product Segment (includes corresponding Graph/Chart).............. II-1 Artificial Tears: The First Line of Treatment for Dry Eyes II-2 Current & Future Analysis..............II-3 Developing Countries Display Untapped Potential II-3 Under-reporting of DES Condition Stifles Market Opportunities II-3 Prevalence and Incidence of Dry Eye Syndrome II-4 Table 2: Prevalence of Dry Eye Syndrome Across Select Countries (in %) (includes corresponding Graph/Chart) II-4 Select Stats on Prevalence Rates II-5 Concentrated Prescription Dry Eye Products Market Benefits OTC Market.............. II-5 Aging Population - A Major Growth Driver II-5 Table 3: Global Population Demographics (2014 & 2020P): Percentage Breakdown of Population by Age Group - Below 40 Years and 40 Years & Above (includes corresponding Graph/Chart).............. II-6

Table 4: Global Population Statistics for 65+ Age Group (2014) (includes corresponding Graph/Chart) II-7 Market Challenges.............. II-8 Lack of Clear Product Differentiation Leads to Confusion II-8 Drug Formulation Fraught with Difficulties II-8 Low Patient Compliance Limits Market Opportunities II-8

2. NOTEWORTHY MARKET TRENDS..............II-9 Preference for Preservative-Free Artificial Tears on Rise II-9 Ongoing Technology Evolution Boosts Growth II-9 Artificial Tears for Dry Eye Syndrome-Single-use (Unit dose) II-10 Artificial Tears for Dry Eye Syndrome -Multi dose II-10 Management of Dry Eyes Post Eye Surgery Drives Demand II-10 Growth in Mobile Workforce and Number of Smartphone Addicts Augurs Well for Market Growth II-11 Rise in Contact Lens Wearers - Another Opportunity Market II-12 Table 5: Penetration of Contact Lenses in Select Countries/Regions (2013) (includes corresponding Graph/Chart) II-13 Focus Grows on Formulating the Right Artificial Tears for Contact Lens Wearers..............II-13 Environmental Factors - Playing an Important Role II-14 Nanotechnology and Other Innovative Delivery Techniques Gain Attention in DES Treatment..............II-14 Direct-to-Customer Promotions: A Primary Marketing Strategy II-15

3. DRY EYE SYNDROME - INDUSTRY DYNAMICS II-16 Multi-Factorial Nature of Dry Eye Poses Challenges to Drug Makers II-16 Bridging Chasm between Diagnosis and Treatment of Dry Eye Syndrome.............. II-16 Competition.............. II-17 Leading Drugs in the Pipeline..............II-17 Shire Plc Eyes FDA Re-submission after Positive Phase III Results of Lifitegrast..............II-17 First Patients Enrolled in Phase2b/3 of RegeneRx's RGN-259 II-18 Mimetogen's MIM-D3 Promises Huge Potential II-18 Clouds of Uncertainty Looms over Santen's Ikervis II-18 Herantis Pharma Kick Starts Phase 2 Study of Cis-UCA Eye Drops II-19 Mitotech's SkQ1 Displays Positive Results II-19 Novaliq's CyclASol Enters Phase II Development Stage II-19 Drugs in the Late-Stage Pipeline for Dry Eye Treatment (2015) II-19 Other Promising Solutions in the Artificial Tear Market II-20 Retaine MGD.............. II-20 Rebagen.............. II-20 Tofacitinib.............. II-20 Positive Effects of Autologous Serum Eyedrops II-20 Resolvins - Capturing Fancy..............II-21 Oculeve to Continue Testing..............II-21 IL-1 Gains Prominence..............II-21 Role of Steroids in DES Treatment II-21 Carbomer-Based Artificial Tear Formulations II-22 Androgen and Estrogen Receptor Inhibitors II-22

4. PRODUCT OVERVIEW.............. II-23 Dry Eye - A Common Ophthalmic Condition II-23 Causes of Dry Eyes..............II-23 Diagnosis of Dry Eye Syndrome..............II-24 Treatment Strategies..............II-24 Artificial Tears - A Brief Overview II-24 Product Options for Dry Eye Syndrome: Breakdown by Palliative Therapies and Targeted Therapies II-25 KCS Inflammation Cycle..............II-26 Common Symptoms of KCS..............II-26 Risk Factors for Dry Eye Disease II-26 Impact of Dry Eye Syndrome on Routine Daily Life Activities: Ranking based on Intensity of Impact Felt by Patients II-27 Types of Artificial Tears..............II-27 Artificial Tears Usage and Dosage II-28 Drug Contraindications or Interactions II-28 Osmolarity.............. II-28 Table 6: Osmolarity of Select Ocular Brands (includes corresponding Graph/Chart)..............II-29 Alternate Treatment Methods..............II-29 Evolution of Artificial Tears..............II-30 First-Generation.............. II-30 Second-Generation..............II-30 Third-Generation.............. II-30 Fourth-Generation..............II-30 Novel Approaches to Revolutionize Dry Eye Therapy II-30 Anti-Inflammatory Drugs..............II-31 Mucin Secretagogues..............II-31 Hormonal Therapies.............. II-31 Omega-3 Drugs.............. II-31 Muco-Mimetics.............. II-31 Barrier-function Drugs..............II-31

5. PRODUCT LAUNCHES/APPROVALS/ INTRODUCTIONS II-32 Allergan Submits PAS for RESTASIS MDPF II-32 NICE Issues FAD Recommending Santen's IKERVIS for Severe Keratitis.............. II-32 Allergan plc Launches REFRESH OPTIVE Gel Drops II-32 URSAPHARM Collaborates with Novaliq and Launches EvoTears II-32 Shire plc Announces FDA's Priority Review Designation for Lifitegrast.............. II-32 Avizorex Pharma Receives Patent for AVX-102 II-32 SilkTears Develops HXP-27 Protein for Tear Formulations II-33 Bausch & Lomb Launches Soothe® Xtra Protection (XP) Eye Drops II-33 Santen Europe Launches Ocutears® in Bulgaria II-33 Similasan Introduces Similasan Complete Eye Relief II-33 Nicox S.A. Announces European Launch of Xailin™ II-33 DiagnosTear Receives Approvals to Start Clinical Study with TeaRx II-33 Neuroptis Bitoech Announces Positive Preclinical Trial Results of ML7 Eye Drops.............. II-33 Santen Pharmaceuticals Launches OTC Eye Drops Soft Santear II-34 Bausch & Lomb Acquires License for Mimetogen's MIM-D3 II-34 Candorvision Launches Hylo™ for Dry Eye Disease II-34

6. RECENT INDUSTRY ACTIVITY..............II-35 Allergan and Pfizer Enter Into Merger Agreement II-35 Allergan Enters into Licensing Agreement with Mimetogen for Tavilermide.............. II-35 Shire Acquires Foresight Biotherapeutics II-35 BioLight Life Sciences Enters Into Collaboration Agreement with Ora, Inc............... II-35 Collaboration between Valeant and Croma to Expand Bausch + Lomb's Portfolio.............. II-35 NovaMedica and SIFI Enter Into Marketing Agreement II-35 NicOx S.A. Acquires Eupharmed Srl II-35

7. FOCUS ON SELECT GLOBAL PLAYERS..............II-36 Abbott Medical Optics Inc. (US)..............II-36 Allergan, Inc. (US).............. II-36 Akorn, Inc. (US).............. II-37 Bausch & Lomb Incorporated. (US) II-37 Johnson & Johnson (US)..............II-38 Novartis International AG (Switzerland) II-38 Alcon, Inc. (Switzerland)..............II-38 Santen Pharmaceuticals Co, Ltd. (Japan) II-39 Novagali Pharma S.A. (France) II-39

8. GLOBAL MARKET PERSPECTIVE..............II-40 Table 7: World Recent Past, Current & Future Analysis for Artificial Tears by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 Through 2020 (includes corresponding Graph/Chart).............. II-40

Table 8: World Historic Review for Artificial Tears by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 Through 2013 (includes corresponding Graph/Chart) II-41

Table 9: World 14-Year Perspective for Artificial Tears by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)..............II-42

III. MARKET

1. THE UNITED STATES.............. III-1 A.Market Analysis.............. III-1 Current and Future Analysis..............III-1 Table 10: Prevalence of Dry Eye in the United States for the Years 2006, 2009, 2012, & 2015 (In Millions of Individuals) (includes corresponding Graph/Chart) III-1

Table 11: Number of Individuals Treated for Dry Eye in the United States (In 000s) for the Years 2006, 2009 & 2012 (includes corresponding Graph/Chart) III-1 Demographics Remain an Important Growth Driver III-2 Table 12: US Population Demographics (2015-2030): Percentage Breakdown of Population by Age Group (includes corresponding Graph/Chart)..............III-2

Table 13: Prevalence of Dry Eye Condition in the US (2014) (includes corresponding Graph/Chart) III-3

Table 14: US Women Population (2015-2030): Percentage Breakdown of Population by Age Group (includes corresponding Graph/Chart)..............III-3 Eye Care Market Thrives Due to Lifestyle and Environmental Factors.............. III-3 Air Pollution Bears Close Association with DES Risk III-4 Thriving OTC Market Offers Good Potential for Artificial Tears III-4 Restasis- The Leading Drug for Dry Eyes III-4 Product Launches..............III-5 Strategic Corporate Developments III-6 Select Players.............. III-6 B.Market Analytics..............III-9 Table 15: US Recent Past, Current & Future Analysis for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 Through 2020 (includes corresponding Graph/Chart)..............III-9

Table 16: US Historic Review for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 Through 2013 (includes corresponding Graph/Chart) III-10

2. CANADA.............. III-11 A.Market Analysis.............. III-11 Current and Future Analysis..............III-11 Product Launch.............. III-11 B.Market Analytics..............III-11 Table 17: Canadian Recent Past, Current & Future Analysis for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 Through 2020 (includes corresponding Graph/Chart) III-11

Table 18: Canadian Historic Review for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 Through 2013 (includes corresponding Graph/Chart).............. III-12

3. JAPAN.............. III-13 A.Market Analysis.............. III-13 Current and Future Analysis..............III-13 Eye Care Products Targeting Specific Consumer Segments Drive the Market.............. III-13 Table 19: Japanese Eye Care Market by Leading Player (2015): Percentage Share Breakdown of Revenues for Rohto Pharmaceutical, and Others (includes corresponding Graph/Chart).............. III-13 Product Launch.............. III-14 Select Players.............. III-14 B.Market Analytics..............III-15 Table 20: Japanese Recent Past, Current & Future Analysis for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 Through 2020 (includes corresponding Graph/Chart) III-15

Table 21: Japanese Historic Review for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 Through 2013 (includes corresponding Graph/Chart).............. III-16

4. EUROPE.............. III-17 A.Market Analysis.............. III-17 Current and Future Analysis..............III-17 Ophthalmic Pharmaceutical Drugs Market in Europe III-17 Artificial Tears Reimbursement Overview III-17 B.Market Analytics..............III-18 Table 22: European Recent Past, Current & Future Analysis for Artificial Tears by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 Through 2020 (includes corresponding Graph/Chart).............. III-18

Table 23: European Historic Review for Artificial Tears by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 Through 2013 (includes corresponding Graph/Chart) III-19

Table 24: European 14-Year Perspective for Artificial Tears by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)..............III-20

4a. FRANCE.............. III-21 A.Market Analysis.............. III-21 Current and Future Analysis..............III-21 High Pollen Count Boosts Eye Care Market III-21 Table 25: French Eye Care Market by Leading Player (2015): Percentage Share Breakdown of Revenues for Johnson & Johnson Santé Beauté, Laboratoires Pierre Fabre, and Others (includes corresponding Graph/Chart) III-21 Product Launches..............III-21 Strategic Corporate Development III-22 B.Market Analytics..............III-22 Table 26: French Recent Past, Current & Future Analysis for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 Through 2020 (includes corresponding Graph/Chart)..............III-22

Table 27: French Historic Review for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 Through 2013 (includes corresponding Graph/Chart) III-23

4b. GERMANY.............. III-24 A.Market Analysis.............. III-24 Current and Future Analysis..............III-24 Digitalised Lifestyle Promotes Eye Care Market III-24 Table 28: German Eye Care Market by Leading Player (2015): Percentage Share Breakdown of Revenues for Gerhard Mann Chem-Pharm Fabrik, and Others (includes corresponding Graph/Chart).............. III-24 Product Launch.............. III-24 B.Market Analytics..............III-25 Table 29: German Recent Past, Current & Future Analysis for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 Through 2020 (includes corresponding Graph/Chart)..............III-25

Table 30: German Historic Review for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 Through 2013 (includes corresponding Graph/Chart) III-26

4c. ITALY.............. III-27 A.Market Analysis.............. III-27 Current and Future Analysis..............III-27 Dry Eye Syndrome Drives Eye Care Product Market III-27 B.Market Analytics..............III-27 Table 31: Italian Recent Past, Current & Future Analysis for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 Through 2020 (includes corresponding Graph/Chart)..............III-27

Table 32: Italian Historic Review for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 Through 2013 (includes corresponding Graph/Chart).............. III-28

4d. THE UNITED KINGDOM..............III-29 A.Market Analysis.............. III-29 Current and Future Analysis..............III-29 High Smartphones' and Tablets' Usage Drive Eye Care Product Market.............. III-29 Product Launch.............. III-29 Strategic Corporate Development III-29 Spectrum Thea Pharmaceuticals Limited - A UK Key Player III-30 B.Market Analytics..............III-30 Table 33: UK Recent Past, Current & Future Analysis for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 Through 2020 (includes corresponding Graph/Chart)..............III-30

Table 34: UK Historic Review for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 Through 2013 (includes corresponding Graph/Chart) III-31

4e. SPAIN.............. III-32 A.MARKET ANALYSIS.............. III-32 Current and Future Analysis..............III-32 Product Launch.............. III-32 B.Market Analytics..............III-33 Table 35: Spanish Recent Past, Current & Future Analysis for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 Through 2020 (includes corresponding Graph/Chart)..............III-33

Table 36: Spanish Historic Review for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 Through 2013 (includes corresponding Graph/Chart).............. III-34

4f. RUSSIA.............. III-35 A.Market Analysis.............. III-35 Current and Future Analysis..............III-35 Cost-Minded Consumers Restrain the Market III-35 Strategic Corporate Development III-35 B.Market Analytics..............III-36 Table 37: Russian Recent Past, Current & Future Analysis for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 Through 2020 (includes corresponding Graph/Chart)..............III-36

Table 38: Russian Historic Review for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 Through 2013 (includes corresponding Graph/Chart).............. III-37

4g. REST OF EUROPE.............. III-38 A.Market Analysis.............. III-38 Current and Future Analysis..............III-38 Product Launches..............III-38 Strategic Corporate Development III-38 Key Players.............. III-39 B.Market Analytics..............III-40 Table 39: Rest of Europe Recent Past, Current & Future Analysis for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 Through 2020 (includes corresponding Graph/Chart) III-40

Table 40: Rest of Europe Historic Review for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 Through 2013 (includes corresponding Graph/Chart).............. III-41

5. ASIA-PACIFIC.............. III-42 A.Market Analysis.............. III-42 Current and Future Analysis..............III-42 Opportunities Abound for Indian OTC Market III-42 B.Market Analytics..............III-43 Table 41: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Tears by Geographic Region - China, India, and Rest of Asia Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 Through 2020 (includes corresponding Graph/Chart) III-43

Table 42: Asia-Pacific Historic Review for Artificial Tears by Geographic Region - China, India, and Rest of Asia Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 Through 2013 (includes corresponding Graph/Chart) III-44

Table 43: Asia-Pacific 14-Year Perspective for Artificial Tears by Geographic Region - Percentage Breakdown of Dollar Sales for China, India, and Rest of Asia Pacific Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-45

5a. CHINA.............. III-46 A.Market Analysis.............. III-46 Current and Future Analysis..............III-46 Modern Lifestyle Trends Boost Eye Care Product Market III-46 Table 44: Chinese Eye Care Market by Leading Player (2015): Percentage Share Breakdown of Revenues for Mentholatum (Zhongshan) Pharmaceuticals Co. Ltd., and Others (includes corresponding Graph/Chart)..............III-46 B.Market Analytics..............III-47 Table 45: Chinese Recent Past, Current & Future Analysis for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 Through 2020 (includes corresponding Graph/Chart)..............III-47

Table 46: Chinese Historic Review for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 Through 2013 (includes corresponding Graph/Chart).............. III-48

5b. INDIA.............. III-49 A.Market Analysis.............. III-49 Current and Future Analysis..............III-49 Prescription-Based Products Dominate the Market III-49 Table 47: Indian Eye Care Market by leading Player (2015): Percentage Share Breakdown of Revenues for Allergan India, and Others (includes corresponding Graph/Chart) III-49 B.Market Analytics..............III-50 Table 48: Indian Recent Past, Current & Future Analysis for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 Through 2020 (includes corresponding Graph/Chart)..............III-50

Table 49: Indian Historic Review for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 Through 2013 (includes corresponding Graph/Chart) III-51

5c. REST OF ASIA-PACIFIC..............III-52 A.Market Analysis.............. III-52 Current and Future Analysis..............III-52 B.Market Analytics..............III-52 Table 50: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 Through 2020 (includes corresponding Graph/Chart) III-52

Table 51: Rest of Asia-Pacific Historic Review for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 Through 2013 (includes corresponding Graph/Chart)..............III-53

6. LATIN AMERICA.............. III-54 A.Market Analysis.............. III-54 Current and Future Analysis..............III-54 Alcon: The Clear Market Leader in Brazilian Eye Care Market III-54 Table 52: Brazilian Eye Care Market by Leading Player (2015): Percentage Share Breakdown of Revenues for Alcon Laboratórios do Brasil, and Others (includes corresponding Graph/Chart).............. III-54 Mexico - Restrained by Inadequate Diagnosis III-54 Table 53: Mexican Eye Care Market by Leading Player (2015): Percentage Share Breakdown of Revenues for Alcon Laboratorios, Laboratorios Sophia, and Others (includes corresponding Graph/Chart)..............III-55 B.Market Analytics..............III-55 Table 54: Latin American Recent Past, Current & Future Analysis for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 Through 2020 (includes corresponding Graph/Chart) III-55

Table 55: Latin American Historic Review for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 Through 2013 (includes corresponding Graph/Chart).............. III-56

7. REST OF WORLD.............. III-57 A.Market Analysis.............. III-57 Current and Future Analysis..............III-57 Product Launch.............. III-57 Strategic Corporate Development III-57 B.Market Analytics..............III-58 Table 56: Rest of World Recent Past, Current & Future Analysis for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 Through 2020 (includes corresponding Graph/Chart) III-58

Table 57: Rest of World Historic Review for Artificial Tears Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 Through 2013 (includes corresponding Graph/Chart).............. III-59

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 68 (including Divisions/Subsidiaries - 74)

The United States (25) Canada (3) Japan (4) Europe (22) - France (3) - Germany (3) - The United Kingdom (5) - Italy (1) - Spain (1) - Rest of Europe (9) Asia-Pacific (Excluding Japan) (17) Africa (2) Middle-East (1)
Read the full report: http://www.reportlinker.com/p0960376-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com


__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com